- Soligenix (NASDAQ:SNGX) announces it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. Brean Capital, LLC served as financial advisor for this transaction.
- Soligenix will file a registration statement with the Securities and Exchange Commission. Once effective, the company will have the right to sell up to $10 million worth of common stock under the terms set forth in the agreement.
- Proceeds from this transaction will be used to help fund the company's ongoing development initiatives of its late-stage product candidates, including its pivotal Phase 3 clinical study of SGX301 in the treatment of cutaneous T-cell lymphoma.
- Related tickers: (XON +1.2%)